

BOVIX MICROCLOX EDC, 600 mg Intramammary Suspension

Authorised

- Cloxacillin

Product identification

Medicine name:

BOVIX MICROCLOX EDC, 600 mg Intramammary Suspension
BOVIX MICROCLOX EDC 600 MG SUSPENSION INTRAMAMMAIRE

Active substance:

Cloxacillin

Target species:

Cattle (dairy cow at drying-off)

Route of administration:

Intramammary use

Product details

Active substance and strength:

Cloxacillin
600.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:

Intramammary suspension

Withdrawal period by route of administration:**Intramammary use:**

-

Cattle (dairy cow at drying-off)

- Meat and offal. no withdrawal period Meat and offal: zero days

- Milk. 48 hour

- if calving occurs at least 42 days after treatment: 48 hours post calving. - if calving occurs less than 42 days after treatment: 44 days after last treatment.

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ51CF02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

France

Package description:

Cardboard box with 12 syringes x 3.6 g of veterinary medicinal product and wipes.

Cardboard box with 24 syringes x 3.6 g of veterinary medicinal product and wipes.

Cardboard box with 60 syringes x 3.6 g of veterinary medicinal product and wipes.

Cardboard box with 120 syringes x 3.6 g of veterinary medicinal product and wipes.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application – bioavailability studies cannot be used to demonstrate bioequivalence (Article 19(1)(b) of Regulation (EU) 2019/6)

Marketing authorisation holder:

Kernfarm B.V.

Marketing authorisation date:

6/02/2025

Manufacturing sites for batch release:

Crida Pharm S.R.L.

Responsible authority:

French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:

FR/V/3515966 3/2024

Date of authorisation status change:

6/02/2025

Reference member state:

Netherlands

Procedure number:

NL/V/0416/001

Concerned member states:

Belgium France Germany Italy Poland Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.